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Case presentation
A 41-year-old white woman was evaluated at Hospital Säo Paulo,
Brazil, for hypertension that had been treated inadequately for 6 years.
She reported pallor, weakness, scotomata, progressive weight loss, and
morning occipital headaches. Three days before admission, she experi-
enced dizziness, blurred vision, intermittent hematuria, shortness of
breath, and orthopnea. The day before admission, she had hemoptysis
and increased shortness of breath.
On physical examination, the patient appeared severely ill; she was
pale and dyspneic, and she had jugular venous engorgement. The blood
pressure was 250/170 mm Hg; pulse rate, 146 beats/mm; and respira-
tions, 36/mm. Funduscopy revealed increased central light reflex of
arteries, arteriovenous nicking, arterial vasospasm, cotton-wool and
hemorrhagic patches, and bilateral papilledema. Rales were detected in
the lower two-thirds of both lung fields. Tachycardia and a gallop
rhythm without cardiac murmurs also were present. There was epigas-
tric tenderness and the liver was enlarged and tender. All peripheral
pulses were present and symmetrical, and there were no bruits. No
edema was present, but muscular wasting of the extremities was
apparent. The electrocardiogram revealed left ventricular hypertrophy
and sinus tachycardia. A plain chest x-ray film revealed an increased
cardiac silhouette and left ventricular enlargement; the pulmonary
circulation was congested.
Laboratory tests revealed the following: blood pH, 7.41; P02, 53 mm
Hg; PCO2, 31 mm Hg; BUN, 83 mg/dI; creatinine, 6.5 mg/dl: serum
sodium, 130 mEq/liter; serum potassium, 4.7 mEq/liter. Urinalysis
revealed 1.5 g/liter of protein with many white blood cells and red blood
cells; hemoglobin, Il g/dl; hematocrit, 33%; white blood cell count,
11,900/mm3 with 82% total neutrophils; platelets, 250,000/mm3; sedi-
mentation rate, 45 mm/hr. The serum CPK was normal; the serum LDH
was elevated (595 U), as was the amylase (565 U). The peripheral
plasma renin activity was 10 ng/ml/hr.
Following admission the blood pressure was reduced to 160/100 mm
Hg by the intravenous administration of diuretics and sodium nitroprus-
side. The pulse rate diminished to 100 beats/mm. and dyspnea
disappeared.
On the following day, the nitroprusside infusion was discontinued for
4 hours, but the blood pressure again rose to 250/170 mm Hg. The
patient was given 150mg of captopril orally, and hemodynamic changes
were measured via a Swan-Ganz catheter. Two hours after captopril
was given, mean arterial pressure decreased from 175 to 140 mm Hg.
and the pulmonary wedge pressure decreased from 5.5 to 3.0 mm Hg.
The cardiac index increased from 3.6 to 4.! liter/m2; no change was
observed in the heart rate.
In spite of continued oral administration of 50 mg of captopril every 6
hours and 40 mg of furosemide every 12 hours, the blood pressure again
soared to the level present on admission. Two days after the first dose
of captopril. another single oral dose of captopril, 50 mg, was adminis-
tered when the blood pressure was 250/140 mm Hg. Neither the arterial
pressure nor any other hemodynamic parameters changed significantly
following this dose. By this time the BUN and plasma creatinine had
risen to 104 mg/dl and 9.7 mg/dl, respectively. After the lack of response
to captopril, 1700 ml of fluid was withdrawn by ultrafiltration over 4
hours. Striking decreases in blood pressure, central venous pressure,
and cardiac index were observed, and administration of normal saline
and packed red cells was necessary to restore intravascular volume.
intravenous nitroprusside therapy again controlled blood pressure. The
following day administration of only alpha-methyldopa (1 g/day) and
furosemide (80 mg/day) kept the blood pressure under control, and the
nitroprusside infusion was discontinued.
Two days after this oral regimen was instituted (3 days after admis-
sion), the blood pressure again rose, and hemodialysis was begun
because of further deterioration of renal function. Several therapeutic
maneuvers, including the use of minoxidil and beta blockers, were tried
without achieving successful control of the hyperten ', and the
patient died from sepsis 9 months later while still in a chro hemodial-
ysis program.
Discussion
DR. OSWALDO RAMOS (Full Profrssor of the Department of
Medicine and Chief of Nephrology Division of Escola Paulista
de Medicina, São Paulo, B"azil): The prevalence of hyperten-
sion in Brazil is similar to that in developed countries. One of
our recent studies, which investigated blood pressure in the
labor force in São Paulo, a major Brazilian industrial center,
revealed that 18.1% of males and 6.6% of females had diastolic
blood pressures higher than 90 mm Hg [11. Another inquiry,
studying a general population in another Brazilian state,
showed that the prevalence of individuals with a diastolic blood
pressure over 95 mm Hg was 11% [21. In our study, 1% of males
were classified as having severe or malignant hypertension. I
might add that unfortunately only 5% of all hypertensive
patients in our study were receiving antihypertensive therapy,
primarily because of economic reasons [Iii. Malignant hyperten-
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sion therefore is an important health problem in Brazil and in
other countries at similar stages of development.
Malignant hypertension classically is characterized by the
presence of elevated blood pressure accompanied by exudates,
hemorrhages, and papilledema in the eye grounds, rapid deteri-
oration of renal function, and the appearance of multiple
arteriolar lesions, with fibrinoid necrosis in the arteriolar wall.
In this presentation, and in the cases studied in our division, we
diagnosed malignant hypertension when high diastolic blood
pressure was accompanied by the presence of bilateral
papilledema.
Clinical aspects
Malignant hypertension, generally a complication of essential
hypertension, rarely occurs in previously normotensive individ-
uals. When it is manifest in a patient with no history of high
blood pressure, renovascular hypertension should be suspect-
ed. Even though malignant hypertension usually follows essen-
tial hypertension, other hypertensive states also can cause it
[31. In the absence of adequate treatment, the prognosis of
malignant hypertension remains dismal: without treatment,
only 25% of patients survive more than one year [4—61.
Blood pressure levels in malignant hypertension, although
elevated, need not be extremely high. Thus, of 50 patients we
studied several years ago, 12% had systolic pressures below 180
mm Hg and diastolic pressures below 120 mm Hg, whereas 24%
had systolic pressures above 260 mm Hg and 25% had diastolic
pressures higher than 180 mm Hg [7]. Patients with malignant
hypertension have evidence of generalized arteriolar damage
causing functional deterioration in many organ systems. The
brain, heart, and kidneys are most noticeably involved. The
usual prevalence of the major signs and symptoms is illustrated
in the 50 patients we studied: headache, 86%; proteinuria, 85%;
visual blurring, 80%; dizziness and vertigo, 72%; other urinary
alterations, 63%; abdominal pain, 59%; weakness, 49%; heart
failure, 37%; and neurologic alterations, 31% [7]. These figures
do not differ from those reported in the literature in the 1950s [3,
8].
Headache is doubtlessly the most common symptom of the
disease and also the earliest, since it seems to precede the full
clinical picture by about 6 months. In our survey [7], the
headache was typically occipital in location and more intense
when the patient awakened in the morning. Hypertensive
encephalopathy, the most frequent neurologic manifestation of
malignant hypertension, was characterized by the sudden onset
of headache, nausea, vomiting, and at times confusion. The
encephalopathy might be due to mild cerebral edema resulting
from a breakdown of cerebral autoregulation of blood flow.
Blood flow to the brain is usually kept constant despite wide
variation in perfusion pressure [9, 10]. When the increase in
perfusion pressure is excessive, however, autoregulation
breaks down and segmental arteriolar dilations and cerebral
edema can occur [10, II].
A frequent but poorly explained finding in most series of
malignant hypertension is weight loss, which affected 56% of
our patients [71 and 75% of Kincaid-Smith's [31. Weight loss is
accompanied by muscle wasting, and perhaps is caused by the
reduced blood supply to the muscles, which in turn is due to
generalized arteriolar damage. Some weight loss also might be
explained by excess salt and water lost by the kidneys, a
phenomenon well documented in the early phase of malignant
hypertension [12—141.
Arterial hypertension causes a substantial pressure load on
the left ventricle; as a consequence, left ventricular hypertro-
phy is frequently observed on the electrocardiogram. Left
ventricular hypertrophy occurred in one-third and was associat-
ed with alterations in the T waves in another one-half; isolated
T-wave alterations were observed in another 10% [7]. Cardiac
arrhythmias were seen in 37% of our 50 patients [7], and the
electrocardiogram was normal in only 10%.
Proteinuria is a frequent finding in malignant hypertension
and can reach nephrotic range. In 15% of the patients we
studied, however, no proteinuria was detected at first examina-
lion [71. In the absence of treatment, renal function rapidly
deteriorates in all cases even though it may be near normal
initially. Although hypertension can result from chronic renal
disease, as a rule renal failure in patients with malignant
hypertension is the consequence rather than the cause of the
severe hypertension.
Vascular lesions in malignant hypertension
The arteriolar lesions of malignant hypertension are found in
many organs, including brain, pancreas, heart, intestine,
spleen, and kidney [3, 15, 161. Two different renal lesions have
been described in malignant hypertension: fibrinoid necrosis
and proliferative arteritis. This combination of lesions is also
called hyperplastic arteritis, fibrinoid intimal hyperplasia, and
musculo-mucoid intimal hyperplasia. Fibrinoid necrosis is the
most characteristic lesion [4, 17, 18] and presumably results
from the leakage of fibrin and other plasma elements into the
arteriolar wall. This lesion is recognized by a fibrillar, homoge-
nous, eosinophilic material composed of fibrin, connective
tissue matrix, and necrotic muscle cell debris in the wall of the
blood vessel. The second lesion, proliferative arteritis, is char-
acterized by marked thickening of the intima due mainly to the
presence of smooth muscle cells, basement membrane material,
and acid mucopolysaccharide; as a result the vascular lumen
progressively narrows. Proliferative endarteritis seems to occur
more frequently in some American blacks than in other subsets
of patients with malignant hypertension [191. This same lesion
can arise in settings other than malignant hypertension, for
example, in scleroderma and after prolonged dialysis [19].
Many studies dating as far back as the l950s have demonstrated
that prompt and total correction of the hypertension, regardless
of the therapeutic agents used, halts or reverses the arteriolar
damage [20, 21].
The precise sequence of events that links high blood pressure
to the arteriolar lesions is still being worked out. One hypothe-
sis is that the permeability of the arterial wall increases because
of alternating contraction and dilation of the arterial vessels.
This hypothesis is based on the studies by Byron [22] and Giese
[23]. Giese, utilizing radioactive colloidal carbon, demonstrated
increased permeability of the vascular wall only in the dilated
segments [23]. These findings were confirmed in electron
microscopic studies of rat mesenteric arterioles [241. In this
investigation, Goldby and Beilin showed that severe hyperten-
sion caused an increase in the number of dilated segments,
whereas correction of the hypertension eliminated both the
constriction and dilation. The increased permeability of the
arteriolar wall also returned to normal. According to the
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Laplace law, for a given level of blood pressure, the larger the
dilation of the vessel, the greater will be the stress on the
vascular wall. Thus dilation of a vessel wall, such as that
demonstrated by these studies, intensifies the effects of hyper-
tension on the vascular wall and favors the infiltration of plasma
into the vascular wall. As a consequence of progressive dila-
tion, the endothelium becomes damaged, permitting plasma to
infiltrate the vascular wall, thus compressing and destroying
smooth muscle cells. The plasma accumulated in the subintima
causes further narrowing and, at times, occlusion of the lumen
of small vessels as well as edema of the neighboring tissues.
This accumulation of plasma in the vessel wall was referred
to as "plasmatic vasculosis" in some of the earlier literature
[25—27]. The fibrinogen in plasma is converted into fibrin when
it contacts cell components. This fibrin plus the concomitant
necrosis of smooth muscle cells comprise the lesion called
fibrinoid necrosis. The damaged endothelium in turn attracts
platelet microthrombi and provokes localized intravascular
coagulation with local platelet consumption, and even thrombo-
cytopenia. The fibrin deposits also can induce red blood cell
aggregation followed by red cell fragmentation and hemolysis,
that is, the microangiopathic hemolytic anemia of malignant
hypertension [281.
The available data clearly demonstrate that high blood pres-
sure per se is the fundamental cause of the vascular lesions [29,
30]. Evidence also indicates that the degree of arterial damage
in experimental animals and in humans with hypertension tends
to parallel the level of blood pressure [20, 21, 31, 32]. This
finding, however, does not preclude the possibility that vaso-
constricting substances in general, and angiotensin in particu-
lar, might be important in the genesis of the vascular lesions of
malignant hypertension. These vasoactive substances may act
not only by increasing blood pressure but also by increasing
vessel wall permeability.
We believe that, in fact, there are two major mechanisms that
cause the vascular lesions of malignant hypertension. One is the
high blood pressure per Se; the second is the effect of hormones,
particularly angiotensin, on vascular permeability. In our own
experience, approximately 75% of patients with malignant
hypertension have an increase in plasma renin activity and,
consequently, have elevated plasma angiotensin and aldoster-
one levels. Angiotensin acts directly on the smooth muscular
cell of the vascular wall [33, 34]. Specific angiotensin receptors
have been demonstrated in a microsomal fraction of vascular
cell muscle, and displacement of calcium ions from these
microsomal particles follows angiotensin-receptor interaction
[35, 36]. In addition to its well-known arteriolar constrictor
action, angiotensin II (as well as other vasopressor agents)
increases the permeability of the vascular wall by causing
contraction of the endothelial cells and altering the endothelial
junctions [36]. This increased permeability facilitates aggrega-
tion of circulating platelets. The platelets immediately contract
and degranulate, thereby releasing serotonin and histamine,
among other substances. These substances also increase endo-
thelial contraction and vascular permeability, thus favoring
further the movement of plasma into the vascular wall.
In malignant hypertension, the increase in angiotensin levels
can be primary, as in patients with stenosis of a major renal
artery. In most patients, however, the increase in angiotensin is
secondary to renal arteriolar constriction due to the increased
hypertension per Se. In essence, a vicious cycle is created in
which hypertension causes greater vascular permeability,
which ultimately induces narrowing of the arteriolar lumen and
consequent stimulation of the renin-angiotensin system, which
in turn can cause a further increase in the permeability of the
vascular endothelium as I noted earlier [371.
These findings favor our hypothesis that both angiotensin-
mediated vasoconstrictor and increased permeability effects are
important in producing the vascular damage of malignant hyper-
tension. However, malignant hypertension can occur even
when the angiotensin levels are very low; as examples, malig-
nant hypertension can be induced in rats by deoxycorticoster-
one administration [12, 381, and occurs, albeit rarely, in primary
hyperaldosteronism in humans [391.
Vasopressin has been suggested as the mediator of the
vascular damage in the DOCA-salt model of hypertension in
rats and I will now review the experimental data regarding this
hypothesis.
In the DOCA-salt, low-angiotensin model of malignant hyper-
tension in rats, Mohring and coworkers noticed that immediate-
ly following the well-known sodium and water diuresis, the
plasma concentration of arginine vasopressin increased many-
fold [40]. A significant increase in plasma vasopressin concen-
tration also has been found during the course of the high-renin
malignant hypertension in rats [411. In these two types of
malignant hypertension in rats, a specific serum antibody
against arginine vasopressin decreases the blood pressure [40,
41]. Additionally, a direct and reciprocal interaction between
arginine vasopressin and angiotensin II has been suggested in
physiologic [42—44] and hypertensive [40, 41] states. Evidence
countering the argument that vasopressin is a cause of vascular
damage in malignant hypertension also has been adduced.
Rabito, Carretero, and Scicli showed that administration of an
arginine vasopressin antagonist did not induce significant
changes in the mean blood pressure either in DOCA-salt,
malignant hypertension or in two-kidney, one-clip Goldblatt
malignant hypertension [45].
Woods and colleagues, using a high-renin model of malignant
hypertension in vasopressin-deficient rats, concluded that argi-
nine vasopressin does not play a primary role in the pathogene-
sis of this model of malignant hypertension [46]. Their conclu-
sion is based on the fact that the development and severity of
hypertension either functionally or histologically were about
the same in rats with and without arginine vasopressin deficien-
cy. Moreover, similar elevations of plasma angiotensin II levels
in both groups of rats indicate that the renin-angiotensin system
does not "compensate" in any way for the lack of arginine
vasopressin [46].
Finally, to offer a provisional conclusion about the pathogen-
esis of vascular lesions in malignant hypertension, I will quote
Gavras et al: ". . . in addition to the mechanical effect of high
blood pressure, a number of other factors determine the occur-
rence and severity of hypertensive vascular injury: vasoactive
hormones, sodium kinetics and changes in blood rheology
[471."
Converting enzyme inhibition in malignant hypertension
Plasma renin activity is elevated in most patients with malig-
nant hypertension [481 but the significance of this increase has
not yet been completely clarified. We do not know whether the
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Fig. 1. Mean arterial pressure (MAP) values in 12 patients with
malignant hypertension receiving taptopril or caplopril plus firose-
mide. See text for details. (Data from Ref. 49).
increase in renin causes malignant hypertension, or whether the
renin increase merely represents a nonspecific response to renal
isehemia. The availability of a converting enzyme inhibitor
made possible testing of the hypothesis that the renin-angioten-
sin system is involved in the pathogenesis of the hypertension,
and allowed evaluation of whether blockade of this system is
valuable therapeutically. We treated 12 patients with malignant
hypertension according to the following protocol [49]. Captopril
was given orally in an initial dose of 150 mg shortly after each
patient was admitted to the hospital. The blood pressure was
measured every 15 minutes, and a second oral dose of 150mg of
captopril was given if the diastolic pressure had not fallen below
130mm Hg. If the diastolic pressure still exceeded 130mm Hg
after the second dose, oral ftirosemide, 40 mg, was added to the
therapeutic regimen.
Figure 1 illustrates that a single oral dose of 150 mg of
captopril lowered blood pressure to normal in 8 of 12 patients
with malignant hypertension [49]. The response occurred within
15 minutes after the drug was administered; the maximal effect
was observed between 60 and 90 minutes. In 4 patients the
initial depressor response was not adequate, and a second dose
of captopril was necessary. In one of these 4 patients, captopril
alone did not decrease the blood pressure significantly, hut the
addition of furosemide brought the blood pressure virtually to
normal (Fig. 1). We found a statistically significant correlation
between the basal plasma renin activity and the decrease in
blood pressure in these 12 patients (r = 0.91). These data
indicated that oral captopril could promptly decrease blood
pressure for at least short periods in the majority of patients
with malignant hypertension. Furthermore, the increase in
blood pressure seemed to be related to an increased activation
of the renin-angiotensin system [48, 50].
Similar therapeutic value for converting enzyme blockade
during hypertensive crisis also was shown by Tuft and col-
leagues [511. Because of these preliminary findings, we have
conducted a cooperative study to evaluate the effectiveness of
captopril in a separate group of 89 patients in hypertensive
crisis that did not respond to furosemide, whether or not the
patients were in the malignant phase [521. Hypertension was
controlled acutely in 69 of these 89 patients when variable oral
doses of captopril were used (Fig. 2); 36 patients responded to
50 mg, 24 to 100 mg, and 9 required 150 mg. Although oral
eaptopril alone is a useful agent in acute hypertensive emergen-
cies, it does not by itself provide sustained control of blood
pressure in most patients with malignant hypertension. All the
patients we studied required a diuretic plus beta or alpha-i
blocking agents for sustained control [49]. In all patients,
addition of a diuretic was necessary within 24 to 36 hours after
the initial dose of captopril was given. The reasons for the lack
of sustained response are not known.
To explore further the blood pressure response to captopril,
we performed hemodynamic studies in a separate group of 11
patients with malignant hypertension [53]. These 11 patients
received 150 mg of captopril orally; blood pressure, cardiac
output, and pulmonary pressure were monitored for 4 hours.
Eight of the II patients responded to captopril, with mean
arterial pressure falling by 20 mm Hg or more. The fall in total
peripheral resistance correlated highly with the prevailing levels
of plasma renin activity (r = 0.72, P <0.01).
Previous studies of the response to captopril in patients with
nonmalignant hypertension indicated that cardiac index did not
increase [50, 541. In contrast, our studies in these 11 patients
showed that the cardiac index increased significantly from 3.29
0.13 to 3.68 0.15 liter/mm2 (range, -2 to 24%) (P < 0.001)
within 2 hours after captopril administration [53]. This phenom-
enon was not associated with changes in blood volume or
distribution. The degree of anemia did not seem to explain the
increase in cardiac output, nor did the presence of heart failure
account for the unexpected results. We hypothesize that in
malignant hypertension the high levels of peripheral resistance
prevent cardiac output from increasing to higher than normal
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Fig. 2. Mean arterial pressure responses to the combination oflfurose-
mide and diazepam plus one or more doses of captopril (CAP) in 89
patients during hypertensive crisis. (Reproduced from Ref. 52).
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levels. Thus, the vasodilation induced by angiotensin blockade
merely unmasks the underlying hyperkinetic status of the
circulation [53].
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of kininogen (Kgn), as determined by trypsin (Try) or
human urinary kallikrein (I-lu Uk) and of kinin potenhiating factor
(KPF). BK refers to bradykinin; LBK refers to lysyl-bradykinin. Open
bar denotes normal controls (n = 10), striped bar denotes patients with
mild to moderate essential hypertension (n = 16), and solid bar denotes
patients with malignant hypertension (n = 12). (Reproduced from [64]
by permission of the American Heart Association, Inc.)
In addition to the renin-angiotensin system, other hormonal
systems might participate in the pathogenesis of malignant
hypertension. For example, a deficiency of prostaglandin pro-
duction has been described in human essential hypertension
[55], and prostaglandin excretion diminished in hypertensive
subjects following furosemide administration [56]. Neverthe-
less, as pointed out in a recent review [57], more clear-cut
evidence of the role of prostaglandins in human hypertension is
needed.
Kinins, known to be potent vasodilators, do exert a marked
influence on renal water and electrolyte excretion [58—60]. The
role of the kallikrein-kinin system in human hypertension has
been the subject of investigation for some time. Most studies
support the hypothesis that urinary excretion of kallikrein is
decreased in human essential hypertension; however, this is not
a universal finding [60, 61]. Urinary kallikrein excretion is
increased in a large majority of patients with hyperaldosteron-
ism, but Lawton et al could find no significant correlation
between urinary kallikrein excretion and aldosterone or plasma
renin activity [621. Lee et al documented the presence of a
defect in the kallikrein-kinin system in rats with malignant
hypertension [63]. We evaluated the kallikrein-kinin system in
human malignant hypertension through measurement of plasma
levels of kininogen (Kgn) [64]. As illustrated in Figure 3, plasma
levels of Kgn diminished dramatically in 12 patients with
malignant hypertension as compared to 10 normotensive con-
trols and 16 patients with mild to moderate essential hyperten-
sion. The reason for the fall in Kgn is not clear but might reflect
increased consumption, diminished synthesis of the kinin pre-
cursors, or both. This fall affects both forms of Kgn in plasma,
that is, low- and high-molecular-weight kininogen, and persists
for at least 3 months after blood pressure has been controlled.
Further studies are needed to determine why Kgn levels are
low, but these observations permit the speculation that a
decreased activity of the kallikrein-kinin system might be
involved in the pathogenesis of malignant hypertension in some
patients.
A detailed discussion of the therapy of malignant hyperten-
sion is beyond the scope of this presentation; because this
subject has been reviewed extensively, I will limit my com-
ments to general guidelines for treatment.
Malignant hypertension remains a clinical emergency, and
the patient should be hospitalized immediately for intensive
treatment. The goal of therapy is to lower arterial pressure to
normal as rapidly as possible without further impairing blood
perfusion to vital organs. To achieve this goal, initially one must
use drugs with a powerful and immediate vasodilating action.
Diuretics should be employed in parallel to potentiate the
response to the vasodilators and to counteract the salt retention
induced by the vasodilators.
The most powerful parenteral vasodilating agent available is
sodium nitroprusside. All reported applications of the drug in
humans and animals with hypertension have yielded excellent
results [65]. The drug's immediate but transitory action requires
that it be administered by continuous infusion under close
medical supervision. We routinely use sodium nitroprusside
infusion (0.2 mg/mI) as the initial treatment of malignant arterial
hypertension. In one series of 64 patients with malignant
hypertension who were admitted to our hospital (but who did
not receive captopril), the average infusion of sodium nitroprus-
side was 6.8 mg/br, with minimum and maximum values of 1.4
mg/hr and 14.0 mg/hr respectively (unpublished data). In most
patients, the arterial pressure was controlled within minutes
after the infusion began. We were able to discontinue giving the
drug between 6 and 300 hours later. The use of nitroprusside not
only provided rapid control of arterial pressure, but permitted
most patients to respond to previously ineffective antihyperten-
sive regimens. The exact explanation for this finding is not
known.
Another potent vasodilator useful in malignant hypertension
is diazoxide administered as a bolus or as a slow infusion [66].
Its hypotensive effect is immediate, and the blood pressure
usually stabilizes during the first few hours. The duration of the
response is 2 to 12 hours, with a usual mean of 6 to 8 hours. As
mentioned earlier, in our hands the use of a converting enzyme
inhibitor is a reasonable therapeutic alternative for malignant
hypertension [49, 52, 53]. Favorable results also have been
reported with minoxidil, a potent direct vasodilator [67, 68].
Calcium channel blocking agents, particularly nifedipine, also
have been used for acute control of hypertension but their
specific place in the therapy of malignant hypertension is
unsettled.
After we control the arterial pressure, we continue therapy
using thiazide diuretics when renal function is reasonably
preserved, or using loop diuretics when an appreciable degree
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of renal impairment is present. Because of the increasing
evidence that a hyperkinetic circulation is present in malignant
hypertension [53, 691, we routinely use beta blockers (such as
propranolol, daily doses of 320 mg or more), alpha-blockers (for
example, prazosin, in doses varying between 3 and 12 mg/day),
or centrally acting alpha agonists (aipha-methyldopa or
clonidine).
In our experience the control of arterial pressure in malignant
hypertension, especially during the initial phase of treatment,
can worsen renal function. This decline in renal function is
frequently transitory and is not a contraindication to aggressive
antihypertensive therapy. Patients with considerably impaired
renal function prior to antihypertensive therapy may develop
uremia. In this situation, it is better in the short run to employ
dialysis because in the long run, control of blood pressure may
improve perfusion of the kidney and ultimately renal function.
Rarely, the arterial damage is so extensive that both renal
deterioration and blood pressure become uncontrollable even
with the most aggressive therapeutic programs. As a general
rule, the therapeutic approaches I have outlined have practical-
ly eliminated the need for renal embolization or bilateral
nephrectomy in patients with severe, refractory hypertension
[70, 711.
Let us return to our discussion of the patient presented today,
who had been inappropriately treated for hypertension for
many years. The diagnosis of malignant hypertension was
based on the presence of encephalopathy, episodes of bloody
urine, high diastolic blood pressure and, most important, bilat-
eral papilledema. Funduscopy disclosed arteriovenous nicking
and arterial tortuosity as well as cotton-wool and hemorrhagic
exudates. Weight loss, impaired renal function, increased levels
of plasma renin activity, and overt heart failure all were
present.
The role of angiotensin in maintaining elevated blood pres-
sure was well demonstrated because oral administration of 150
mg of captopril produced a substantial fall in the mean arterial
pressure. This decrease was due to a dramatic reduction of the
total peripheral resistance, which was accompanied by an
increase in the cardiac index.
The acute response to captopril was impressive but ceased
after a few hours. This secondary failure of captopril apparently
was not due to fluid retention, because the withdrawal of 1.7
liters of fluid after 4 hours of ultrafiltration suddenly decreased
blood pressure and central venous pressure to very low levels.
When intravascular volume was restored to normal, blood
pressure returned to the previous high levels. These findings,
coupled with the observation that the blood pressure was
controlled when alpha-methyldopa was administered, suggest-
ed that the elevated blood pressure in this patient might have
been maintained by hyperactivity of the adrenergic system.
Blood pressure subsequently rose again and renal function
deteriorated further, requiring that hemodialysis be instituted.
Despite several different therapeutic regimens, the blood pres-
sure could not be controlled adequately, and the patient died 9
months after the first admission.
Questions and answers
DR. JOHN T. HARRINGTON: Dr. Ramos, can you expand on
your comment that effective treatment of hypertension, even in
patients with severe renal failure, often leads to restoration of
some degree of renal function? Drs. Blythe and Woods at
Chapel Hill many years ago showed that once the BUN rose to
over 90 mg/dl, the likelihood of reversing renal insufficiency
was quite low [72]. Does their conclusion fit with your own
experience?
DR. RAMOS: In general, I certainly agree with the finding of
Blythe and Woods 72]. Recently Lawton claimed that vigorous
antihypertensive treatment of patients with malignant hyperten-
sion resulted in stabilization of renal function in 10% of the
patients, progressive deterioration in about 30%, and transient
deterioration with subsequent improvement in a few weeks in
about 60% [73]. We have not carried out a formal, long-term
followup study on antihypertensive treatment in patients with
malignant hypertension; however, in the 12 patients with malig-
nant hypertension whom we treated initially with captopril [42],
9 were followed for at least 6 months and the outcomes were as
follows: in 7 in whom the initial plasma creatinine levels were
1.4, 2.4, 2.5, 2.6, 3.9, 4.9, and 5.1 mg!dl, respectively, renal
function remained stable or improved slightly. In the remaining
2 patients in whom the initial plasma creatinine levels were 9.0
and 14.5 mg/dl, renal function further deteriorated with treat-
ment, and dialysis was required.
It is my hypothesis that improvement of renal function with
treatment depends on whether the intrarenal arterioles are able
to dilate sufficiently in response to the systemic vasodilation
induced by antihypertensive treatment. In patients in whom
vasodilation of systemic arterioles is greater than that in the
renal arterioles, renal function may deteriorate as the systemic
blood pressure is reduced. In patients treated with captopril,
what happens to renal function is not predictable because
angiotensin II is an important factor in the maintenance of GFR
during states of reduced renal blood flow [74, 75].
DR. NESTOR SCHOR (Nephrology Division, Escola Paulista
de Medicina): How do you explain the fact that whereas most of
your patients with malignant hypertension have an initial salu-
tary response to captopril alone, blood pressure control is not
maintained with the drug chronically?
DR. RAM05: We believe that angiotensin II is a very impor-
tant cause of the high blood pressure in malignant hypertension,
but it is not the only factor. When angiotensin II production is
blocked and blood pressure drops, salt retention becomes an
important factor in maintaining an elevation of blood pressure.
We also observed that the patients with malignant hypertension
who became unresponsive to captopril also became more
responsive to oral sympatholytic agents. This observation sug-
gests that captopril stimulates the sympathetic nervous system
in some way.
DR. HARRINGTON: If captopril does stimulate the sympathet-
ic nervous system, one might speculate that catecholamine
levels in blood or urine would be elevated in patients treated
with captopril, Have you or others measured catecholamine
levels in patients with malignant hypertension before and after
captopril treatment?
DR. RAMOS: No, we did not. My speculation is based on the
observation that adrenergic blockade becomes more effective in
lowering blood pressure following captopril treatment. More-
over, in a study in our laboratory of rats with methyl-predniso-
lone-induced hypertension, prolonged captopril administration
led to increased activity of the sympathetic nervous system
[76].
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DR. R0GERI0 A. MULINARI (Nephrology Division, Escola
Paulista de Medicina): What do you think is the role of ADH in
the pathogenesis of malignant hypertension'?
DR. RAMOS: I believe that ADH might play a role in some
forms of malignant hypertension, but this subject only will be
clarified when a specific ADH antagonist becomes available for
clinical use.
DR. HARRINGTON: Dr. Gary Robertson has measured ADH
levels in a number of different clinical situations [77]. I don't
know the answer to Dr. Mulinari's question, but patients with
the syndrome of inappropriate antidiuretic hormone secretion
due to bronchogenic carcinoma, despite high blood levels of
ADH and volume expansion, usually are not hypertensive [78].
DR. RAMOS: Dr. Saragoça, the presence of congestive heart
failure prior to captopril treatment also could explain the
increase in cardiac output following captopril in the 11 malig-
nant hypertensive patients you studied [40]. Do you have any
comments?
DR. MANOEL A.S. SARAGOcA (Nephrology Division, Escola
Paulista de Medicina): Increases in cardiac output are com-
monly observed in patients with congestive heart failure treated
with vasodilators. Therefore, the increased cardiac output we
observed could be due simply to varying degrees of congestive
heart failure. I don't think this is the case, however, because
only 4 of the 11 patients had low stroke-volume indices, and in
these patients, the reductions were modest when compared
with those usually observed in patients with congestive heart
failure. Furthermore, only 3 of these 4 patients had high
pulmonary wedge pressures. In these 4, a moderate depression
of cardiac pump function could be assumed, but not in the
remaining 8 who had normal pulmonary wedge pressures.
These data corroborate our view of a hyperkinetic circulation in
malignant hypertension that was unmasked by vasodilation
secondary to angiotensin converting enzyme blockade.
DR. HARRINGTON: You mentioned vasospasm of the renal
arteries as one of the functional changes that might influence
whether glomerular filtration rate improves in patients with
malignant hypertension. Have you had any experience using
calcium channel blockers in such patients? Second, are there
any data on renal blood flow in patients with malignant hyper-
tension treated with calcium channel blocking agents?
DR. SARAGOcA: We have observed extremely elevated levels
of renal vascular resistance (RVR = 0.60 0.16 AU)in patients
with malignant hypertension. Although significant decreases in
RVR were observed with converting enzyme blockade (RVR =
0.51 0.06 AU, P < 0.05), these levels still were elevated when
compared to normal standards for our laboratory (approximate-
ly 0.18 AU). The decreases in RVR did not correlate with the
observed decreases in systemic vascular resistance. These
observations suggest that factors other than angiotensin II are
of paramount importance in determining the high intrarenal
resistance to blood flow. The use of calcium channel inhibitors
in malignant hypertension might shed some light on this issue,
but these studies are few and no controlled experiments have
been reported; therefore I cannot answer your questions direct-
ly. Furthermore, a major determinant of the decreased renal
blood flow in patients with malignant hypertension might be of
structural rather than of functional origin.
DR. MARCELL0 MARCONDES (Chief of Nephrology Division,
Faculdade de Medicina da USP): I noticed that 15% of your
patients with malignant hypertension did not have prOteinuria
when first examined. In our experience with malignant hyper-
tension, practically all patients have some degree of protein-
uria. Could you comment on this apparent discrepancy?
DR. RAMOS: The diagnosis of malignant hypertension in some
of our patients was made very early, when renal function was
still well preserved. All patients with malignant hypertension
have some degree of proteinuria if the disease is allowed to
progress. In our study, in which we used routine clinical
methods for detection, we observed proteinuria in 85% of the
patients, and levels varied from 0.18 to 15.5 g/liter [7].
Reprint requests to Dr. 0. Ramos, Disciplina de Nefrologia, Escola
Paulista de Medicina, Rua Botucatu, 720-São Paulo-Brazil
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